Investigating the reasons for low and delayed screening of primary Aldosteronism
Official title: Understanding and addressing the lack of and delayed screening for primary Aldosteronism
Funded at Mayo Clinic Rochester · NIH-11048613 · Data updated 2026-11-12
This study is looking into why not enough people at risk for primary aldosteronism get tested for it, even though it can cause serious health problems, and it aims to find ways to make screening easier and more accessible for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | March 1, 2025 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $726,611 |
| NIH project number | 1R01HL172948-01A1 |
| Project ID | NIH-11048613 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include adults who are at risk for primary aldosteronism, particularly those with hypertension or related cardiovascular conditions.
✕Less likely to help
Patients who do not have hypertension or related risk factors for primary aldosteronism may not benefit from this research.
What this research studies
This research aims to understand why so few individuals at risk for primary aldosteronism (PA) are screened for this condition, which can lead to serious health issues like cardiovascular and renal complications. By examining various factors such as patient demographics, clinician practices, and healthcare system barriers, the study seeks to identify the root causes of inadequate screening. The project will utilize linked datasets, including insurance claims and electronic health records, to analyze current screening patterns and disparities. Ultimately, the goal is to develop interventions that improve the accessibility and timeliness of PA screening for all patients.
Why it matters
Potential benefit: If successful, this research could lead to improved screening rates for primary aldosteronism, resulting in better health outcomes and reduced complications for patients.
How similar studies have gone: Previous research has shown that addressing barriers to screening can improve health outcomes, suggesting that this approach may yield significant benefits.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Brito Campana, Juan P — Mayo Clinic Rochester
- Study coordinator: Brito Campana, Juan P
Related research
Other NIH-funded projects on the same topics.
-
Unrecognized Primary Aldosteronism and Kidney Disease in Diabetes
A study at Brigham and Women’s Hospital will explore whether unrecognized primary aldosteronism contributes to kidney disease and heart risk in people with diabetes.
-
Understanding why primary aldosteronism screening is missing or delayed
A Mayo Clinic-led study aims to understand why many people at risk for primary aldosteronism are not being screened early enough and what can be done to fix it.
-
Understanding heart function and structure in patients with primary aldosteronism
This study is looking at how primary aldosteronism impacts heart health in people with heart failure that still pumps well, and it will explore how a medication called spironolactone might help improve their heart function and structure.
-
Investigating how unrecognized primary aldosteronism contributes to kidney disease in diabetes
This study is looking at how a condition called primary aldosteronism might affect kidney health in people with diabetes, and it aims to find those who may not know they have it so they can get the right care to protect their kidneys.
-
Investigating the causes and effects of primary aldosteronism subtypes
This study is looking at primary aldosteronism, a condition that causes high blood pressure, to find better ways to diagnose it using blood tests and tissue samples, so patients can get the right treatment without needing invasive procedures.
-
Investigating heart function and blood flow in patients with primary aldosteronism.
This study is looking at how a condition called primary aldosteronism impacts heart health in people with heart failure and how a specific type of medication might help improve their heart function by reducing inflammation, so we can find out who might benefit the most from this treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.